List of Excipients in Branded Drug ANTABUSE

Generic Drugs Containing ANTABUSE

Company	Ingredient	NDC	Excipient
Teva Women's Health Inc	disulfiram	51285-523	ANHYDROUS LACTOSE
Teva Women's Health Inc	disulfiram	51285-523	CELLULOSE, MICROCRYSTALLINE
Teva Women's Health Inc	disulfiram	51285-523	MAGNESIUM STEARATE
Teva Women's Health Inc	disulfiram	51285-523	SILICON DIOXIDE

What are the Most Frequently-Used Excipients in ANTABUSE?

# Of NDCs	Excipient
2	ANHYDROUS LACTOSE
2	CELLULOSE, MICROCRYSTALLINE
2	MAGNESIUM STEARATE
2	SILICON DIOXIDE

Antabuse Excipient Strategy and Commercial Opportunities for Disulfiram

Last updated: September 2, 2026

Antabuse is the former brand name for disulfiram, an oral aldehyde dehydrogenase inhibitor used as an alcohol-aversive treatment. Its active ingredient is long off-patent, and the main commercial opportunity is not conventional generic substitution. Value is concentrated in adherence-oriented formulations, taste masking, modified release, combination packaging, and differentiated 505(b)(2) products.

The core excipient strategy should address disulfiram’s practical limitations: poor adherence, unpleasant taste, tablet swallowing burden, oxidation and moisture sensitivity, and the need for reliable oral exposure. No biosimilar pathway applies because disulfiram is a small molecule.

What is Antabuse and how is disulfiram regulated?

Antabuse contains disulfiram, a synthetic thiuram derivative that inhibits aldehyde dehydrogenase. Patients who consume alcohol while taking disulfiram can develop an acetaldehyde-mediated reaction involving flushing, headache, nausea, vomiting, hypotension, and other potentially serious symptoms.

In the United States, disulfiram tablets are approved as prescription drug products. Antabuse is no longer the primary commercial brand in the U.S. market, while generic disulfiram tablets remain the relevant product category. FDA labeling identifies 250 mg and 500 mg oral tablet strengths for disulfiram products. Product availability varies by manufacturer and pharmacy channel.[1][2]

FDA regulatory pathway

A company commercializing a conventional disulfiram tablet can generally pursue an abbreviated new drug application, provided it meets applicable requirements for pharmaceutical equivalence, bioequivalence, quality, labeling, and manufacturing.

A differentiated excipient-based product may require a different pathway:

Product concept	Likely U.S. regulatory pathway	Commercial rationale
Conventional 250 mg or 500 mg tablet	ANDA	Lowest development cost; limited differentiation
Taste-masked tablet	ANDA if equivalence and inactive-ingredient requirements are met; otherwise possible 505(b)(2)	Improves administration and adherence
Orally disintegrating tablet	505(b)(2) or ANDA depending on product design and regulatory precedent	Useful for supervised dosing and swallowing difficulty
Extended-release tablet	505(b)(2) is the more likely pathway	Reduces dosing frequency and may improve adherence
Oral solution or suspension	ANDA or 505(b)(2), depending on reference-product relationship	Supports dose flexibility and administration assistance
Long-acting injectable	505(b)(2) or full NDA pathway	Potentially large clinical differentiation but high development risk
Combination adherence kit	Drug approval plus device, packaging, or labeling analysis	Links dosing with counseling, monitoring, or alcohol-avoidance support

FDA’s inactive ingredient requirements remain central. Excipients must be acceptable for the route, dosage form, concentration, and patient population. The FDA Inactive Ingredient Database can support excipient selection but does not eliminate the need for product-specific safety and quality justification.[3]

What excipients are used in disulfiram tablets?

Disulfiram tablets generally use standard immediate-release solid-dose excipients. Public product labels for generic disulfiram products have identified excipients such as microcrystalline cellulose, lactose or other fillers, povidone, crospovidone or sodium starch glycolate, colloidal silicon dioxide, and magnesium stearate. The exact composition differs by manufacturer and strength.[2]

Excipient class	Typical function	Relevance to disulfiram
Microcrystalline cellulose	Diluent and compression aid	Supports tablet hardness and processability
Lactose or alternative filler	Bulk and compressibility	May create labeling and patient-tolerance considerations
Povidone	Binder	Supports granulation and mechanical strength
Crospovidone or sodium starch glycolate	Superdisintegrant	Controls tablet breakup and dissolution
Colloidal silicon dioxide	Glidant and moisture-management aid	Improves powder flow; may support manufacturing consistency
Magnesium stearate	Lubricant	Reduces sticking and ejection force
Film-coating polymers	Protection, appearance, swallowability	Can support taste masking and moisture protection

The excipient profile of a generic product should not be assumed to match the former Antabuse formulation. FDA labeling and manufacturer-specific prescribing information control the relevant composition for each marketed product.

How should an excipient strategy address disulfiram’s formulation risks?

The most commercially useful excipient strategy should be built around four technical objectives: taste control, rapid but reproducible disintegration, stability, and patient acceptability.

Taste masking

Disulfiram can be difficult to administer because of its unpleasant taste. Taste masking has direct commercial value for orally disintegrating tablets, chewable products, oral granules, and liquid formulations.

Potential approaches include:

• Polymer film coating of drug particles
• Ion-exchange resin complexes
• Lipid or wax microencapsulation
• Hydrophobic matrix systems
• pH-dependent coating
• Cyclodextrin or host-guest complexation
• Multiparticulate pellets in capsules or sachets

The strategy must preserve dissolution after swallowing. Excessive hydrophobic coating can delay release, create food-effect concerns, or produce variable exposure.

A taste-masked ODT could be positioned for patients with swallowing difficulty, supervised administration, and treatment settings where adherence is directly observed. The product would require careful control of mouthfeel, disintegration time, residual bitterness, and dose uniformity.

Moisture and oxidation control

Disulfiram’s sulfur-containing chemical structure creates a reason to evaluate oxidation, hydrolysis, polymorphism, and interaction with excipients during development. A practical stability program should examine:

• Water activity
• Oxygen exposure
• Light sensitivity
• Temperature cycling
• Lubricant concentration
• Aldehyde impurities in excipients
• Residual solvents
• Packaging permeability

High-barrier blister packaging, desiccant-containing bottles, and moisture-resistant film coatings may provide more defensible differentiation than adding a novel excipient alone.

Packaging can also be a meaningful commercial tool. Unit-dose blister packs support adherence tracking and reduce repeated opening of a multidose bottle. Calendar packaging can be paired with counseling materials and supervised dosing protocols.

Disintegration and dissolution control

Immediate-release disulfiram tablets should disintegrate consistently across manufacturing lots and storage conditions. High levels of hydrophobic lubricant, excessive compaction, or overcoating can slow dissolution.

A robust formulation-development program should compare:

• Direct compression versus wet granulation
• Crospovidone versus sodium starch glycolate
• Low- and high-substitution hydroxypropyl cellulose
• Different lubricant levels and blending times
• Tablet hardness versus disintegration time
• Coated and uncoated tablets
• Dissolution in media that reflect relevant gastrointestinal conditions

Dissolution specifications should be linked to bioequivalence risk rather than selected only for manufacturing convenience.

Patient-specific excipient selection

Disulfiram is used in a population that may have liver disease, polypharmacy, nutritional deficits, or poor treatment adherence. Excipients that create avoidable tolerability issues should be minimized.

Potential considerations include:

• Lactose content for patients with lactose intolerance
• Sodium content in high-risk patients
• Polyethylene glycol or sorbitol in liquid formulations
• Alcohol-containing flavors or solvents, which may create a product-specific safety concern
• Colorants and preservatives in pediatric or specialty populations
• Gluten and allergen statements where relevant

Any oral liquid or flavored dosage form requires particular scrutiny because the formulation must not introduce ethanol or another alcohol that conflicts with the product’s therapeutic purpose or labeling.

What formulations are protected by disulfiram patents?

Disulfiram’s basic composition of matter is expired. The commercially relevant patent question concerns formulation, delivery, manufacturing, and method-of-use claims.

Potentially protectable subject matter includes:

1. Taste-masked disulfiram particles or tablets.
2. Extended-release matrices or coated multiparticulates.
3. Orally disintegrating dosage forms.
4. Disulfiram suspensions with defined particle-size distributions.
5. Stabilized compositions with specified antioxidant or moisture-control systems.
6. Long-acting injectable depots.
7. Combination regimens involving disulfiram and adherence-support technologies.
8. Manufacturing processes that improve content uniformity or reduce degradation.

A formulation patent must provide more than a list of conventional excipients. Stronger claims would typically require a defined composition, measurable performance characteristics, and data showing an unexpected benefit such as improved stability, reduced bitterness, controlled exposure, or lower dosing frequency.

Patent estate strength

Patent category	Expected strength for a new entrant	Commercial assessment
Disulfiram active ingredient	Very low	Generic competition is established
Conventional tablet composition	Low	Easy to design around
Specific taste-masking technology	Moderate	Stronger if supported by dissolution and sensory data
Extended-release formulation	Moderate to high	Potentially valuable but requires clinical bridging
Long-acting injectable	High if claims are enabled	High development and regulatory burden
Packaging and adherence system	Low to moderate	Useful as a secondary layer, rarely sufficient alone
Method of treatment	Variable	Risk depends on claim scope and prior art
Manufacturing process	Moderate	Valuable if process is difficult to replicate and non-obvious

When does Antabuse lose exclusivity?

The original Antabuse exclusivity period has expired. Disulfiram is an established generic active ingredient, and conventional tablets do not depend on remaining molecule-level exclusivity.

The relevant exclusivity dates are therefore product-specific:

Exclusivity type	Current relevance
Original active-ingredient patent	Expired
New chemical entity exclusivity	Expired
Conventional generic tablet protection	Generally unavailable as a strategic barrier
Formulation patent	Depends on the specific new product
Method-of-use patent	Depends on claim scope, validity, and listing status
Regulatory exclusivity for a new disulfiram formulation	Could arise only from a qualifying new approval

A new product may receive regulatory protection tied to its own clinical or formulation innovation, but that protection would not block all conventional disulfiram tablets.

What is the Orange Book status of Antabuse and disulfiram?

The Orange Book is relevant to approved drug products, patents, and exclusivity. A company evaluating disulfiram should distinguish among the discontinued Antabuse brand, currently approved generic products, and any newly approved formulation.

For a conventional generic product, the main regulatory issues are abbreviated approval, reference-product selection, labeling, and pharmaceutical equivalence. Paragraph IV exposure becomes more important if a new branded formulation has listed patents.

Because disulfiram has no biosimilar pathway, the commercial dispute is between branded reformulations and generic small-molecule products rather than reference biologics and biosimilars.[4]

Which companies are challenging Antabuse exclusivity?

Generic manufacturers have already established the competitive market for disulfiram tablets. The practical competitive threat to a differentiated product would come from:

• Existing generic tablet suppliers
• Contract manufacturers offering low-cost disulfiram products
• Specialty-pharmacy companies developing adherence packaging
• Drug-delivery companies pursuing depot or extended-release products
• Addiction-treatment companies combining medication with monitoring services

A new branded product would likely face two layers of competition: low-cost immediate-release tablets and non-pharmacologic alcohol-use-disorder services. The product must therefore offer a measurable adherence or administration advantage.

No broad biosimilar competition applies.

What paragraph IV challenges and litigation risks exist?

For legacy conventional disulfiram tablets, Paragraph IV litigation is unlikely to be the principal barrier because the active ingredient is long established and conventional products are genericized.

Paragraph IV risk becomes material when a company launches a new formulation protected by Orange Book-listed patents. Potential litigation issues include:

• Whether the patent claims cover the generic’s excipient system
• Whether the generic has a different release profile
• Whether a taste-masking coating falls within composition claims
• Whether the patent is enabled across the full claim scope
• Whether the patent claims an obvious combination of known excipients
• Whether the generic’s Paragraph IV notice triggers a 30-month stay
• Whether an authorized generic or settlement affects launch timing

For a new disulfiram product, settlement agreements could include delayed generic entry, a licensed formulation, authorized-generic rights, or covenants not to sue. No settlement should be assumed without a product-specific court docket and agreement review.

How does disulfiram compare with other alcohol-use-disorder medicines?

Disulfiram competes with naltrexone, acamprosate, and medication-assisted treatment programs. Its differentiation is behavioral and adherence-dependent: it works best when the patient understands and accepts the alcohol-aversive mechanism and dosing is supervised or supported.

Product	Main administration issue	Excipient opportunity	Competitive position
Disulfiram tablets	Daily adherence and unpleasant taste	ODT, taste masking, modified release, adherence packaging	Low-cost legacy medicine
Naltrexone tablets	Daily adherence; hepatic considerations	ODT and combination adherence systems	Broader prescribing familiarity
Extended-release injectable naltrexone	Injection access and cost	Depot excipients and syringe presentation	Strong adherence advantage
Acamprosate	Multiple daily doses and tablet burden	Modified release and dose simplification	Adherence-sensitive
Disulfiram depot	Need for sustained delivery and controlled exposure	Microspheres, implants, in situ depots	High differentiation, high risk

An injectable or long-acting disulfiram product could command greater pricing power than a tablet, but it would require evidence on dose control, reversibility, safety, local tolerability, and alcohol-reaction management.

What licensing deals could create commercial value?

Licensing opportunities are more likely to involve delivery technology than disulfiram itself. Relevant deal structures include:

• Exclusive rights to a taste-masking platform
• Regional rights for an ODT or oral film
• Use of a long-acting injectable technology
• Co-development with an addiction-treatment provider
• Contract manufacturing plus commercial supply
• Combination of product rights with digital adherence monitoring
• Authorized-generic arrangements for a branded reformulation

The licensor’s value increases when the technology has been used in an approved product, has scalable manufacturing, and has patent claims covering measurable performance rather than a broad excipient combination.

What generic launch risks exist for a new disulfiram product?

A branded reformulation faces several generic-entry scenarios.

Scenario 1: Conventional generic substitution

A branded ODT or taste-masked tablet may still compete with inexpensive standard tablets if payers do not recognize a meaningful adherence benefit. This is the highest-probability commercial threat.

Scenario 2: Formulation-specific generic challenge

If the product receives approval through a pathway that permits generic substitution, a later ANDA applicant may challenge formulation patents through Paragraph IV certification.

Scenario 3: 505(b)(2) competition

Another sponsor could develop a competing modified-release or liquid product under 505(b)(2). The entrant may not need to copy the exact excipient system if it can establish a different formulation and clinical bridge.

Scenario 4: Authorized generic

An authorized generic can reduce the price gap and preserve manufacturing control. This strategy is particularly relevant if the branded product has limited differentiation and payers demand low-cost alternatives.

What geographic coverage matters for disulfiram excipient commercialization?

The United States is the most structured market for Orange Book, ANDA, and Paragraph IV analysis. Europe and other markets apply different rules for generic approval, supplementary protection, formulation patents, and substitution.

A global strategy should evaluate:

• U.S. Orange Book listings and Hatch-Waxman timing
• European national and unitary patent exposure
• Regulatory requirements for modified-release products
• Local acceptance of alcohol-use-disorder pharmacotherapy
• Reimbursement and pharmacy substitution
• Supply-chain access to pharmaceutical-grade excipients
• Manufacturing-site qualification and serialization

A formulation patent filed only in the U.S. leaves significant geographic exposure. Taste-masking and delivery claims should be assessed across the U.S., Europe, Japan, China, Canada, Australia, and priority manufacturing jurisdictions.

How strong is the commercial opportunity for disulfiram excipients?

The opportunity is moderate for oral reformulation and potentially substantial for sustained delivery, but the market is constrained by disulfiram’s low-cost generic status and adherence-dependent clinical use.

Opportunity	Technical feasibility	IP potential	Pricing potential
Improved conventional tablet	High	Low	Low
Taste-masked ODT	Moderate	Moderate	Moderate
Alcohol-free oral liquid	Moderate	Moderate	Moderate
Calendar blister and adherence pack	High	Low	Low to moderate
Extended-release oral tablet	Moderate	Moderate to high	Moderate to high
Long-acting injectable	Low to moderate	High	High
Digital adherence combination	Moderate	Moderate	Depends on reimbursement
Specialty formulation for supervised treatment	Moderate	Moderate	Moderate

The strongest near-term concept is a taste-masked, moisture-protected ODT or multiparticulate product with unit-dose packaging. The strongest long-term concept is a sustained-delivery product, but its clinical and regulatory burden is materially higher.

Key Takeaways

• Antabuse is the legacy brand for disulfiram, an established generic small molecule.
• Active-ingredient exclusivity has expired; conventional tablets have limited patent differentiation.
• Excipient value is concentrated in taste masking, disintegration control, moisture protection, and adherence packaging.
• An ODT or multiparticulate product is more commercially realistic than a conventional tablet reformulation.
• A long-acting injectable could create the largest moat but requires substantial clinical development.
• FDA Inactive Ingredient Database review, product-specific labeling, dissolution testing, and stability studies are central to development.
• Paragraph IV and Orange Book risks primarily concern new formulation patents, not legacy disulfiram tablets.
• Biosimilar competition does not apply.
• Commercial success depends on proving better adherence, administration, or persistence than low-cost generic tablets.

FAQs

Can disulfiram be formulated as an orally disintegrating tablet?

Yes. An ODT could use superdisintegrants, taste-masked drug particles, film coating, and moisture-barrier packaging. The main development risks are bitterness, dose uniformity, dissolution, and storage stability.

Can alcohol be used as an excipient in Antabuse formulations?

Alcohol-containing solvents, flavors, or processing materials would require careful assessment because the product is intended for patients avoiding alcohol. Residual alcohol, labeling, and potential interaction concerns could materially limit the formulation.

Is a disulfiram extended-release tablet commercially attractive?

Potentially. Reduced dosing frequency could address adherence, but a sponsor would need to establish pharmacokinetic performance, dose control, safety, and the clinical relevance of sustained exposure.

Are disulfiram formulation patents likely to block generic tablets?

Usually not. A narrow formulation patent may protect a specific ODT, taste-masking system, or release profile while leaving conventional immediate-release tablets available.

What is the most defensible excipient-based disulfiram product?

A product combining taste-masked multiparticulates, rapid oral disintegration, high-barrier unit-dose packaging, and demonstrated adherence improvement would have a stronger commercial position than a tablet using only a different filler or lubricant.

References

1. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
2. National Library of Medicine. (n.d.). DailyMed: Disulfiram tablet labeling. https://dailymed.nlm.nih.gov/dailymed/
3. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/
4. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book